Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes

  1. Jeffrey J. Molldrem, MD;
  2. Eric Leifer, PhD;
  3. Erkut Bahceci, MD;
  4. Yogen Saunthararajah, MD;
  5. Mary Rivera, RN;
  6. Cynthia Dunbar, MD;
  7. Johnson Liu, MD;
  8. Riotoro Nakamura, MD;
  9. Neal S. Young, MD; and
  10. A. John Barrett, MD
  1. From National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
    1. Figure 1. Five-year probability of survival was 76% (95% CI, 64% to 88%). Dotted lines represent the upper and lower boundaries of confidence intervals. Covariate-adjusted survival for responders and nonresponders. Response status was ascertained at 8 months after treatment with antithymocyte globulin.
      View larger version:
      Figure 1. Five-year probability of survival was 76% (95% CI, 64% to 88%). Dotted lines represent the upper and lower boundaries of confidence intervals. Covariate-adjusted survival for responders and nonresponders. Response status was ascertained at 8 months after treatment with antithymocyte globulin. Overall survival of the 61 patients enrolled in the study.Top.Bottom.
    2. Figure 2. Five-year probability of remaining progression free was 90% (95% CI, 80% to 100%). Dotted lines represent the upper and lower boundaries of confidence intervals. Covariate-adjusted time to progression for responders and nonresponders. Response status was ascertained at 8 months after treatment with antithymocyte globulin.
      View larger version:
      Figure 2. Five-year probability of remaining progression free was 90% (95% CI, 80% to 100%). Dotted lines represent the upper and lower boundaries of confidence intervals. Covariate-adjusted time to progression for responders and nonresponders. Response status was ascertained at 8 months after treatment with antithymocyte globulin. Overall time to progression (to refractory anemia with excess blast cells in transformation or to acute myelogenous leukemia) for the 61 patients enrolled in the study.Top.Bottom.

    Summary for Patients

    • Summaries for Patients:Promising Therapy for Bone Marrow Failure from Myelodysplastic Syndromes Ann Intern Med August 6, 2002 137:I-27
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med August 6, 2002 vol. 137 no. 3 156-163
    1. AbstractFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)
      1. Summary for Patients

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues